Oligomero morfolino fosforodiamidato per skipping dell’esone 45 ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
113筋ジストロフィー1

113. 筋ジストロフィー


臨床試験数 : 646 薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-002069-52-IT
(EUCTR)
19/01/201707/02/2018A research study of a new investigational medicinal product for the treatment of Duchenne Muscular Dystrophy patientsA Double-Blind, Placebo-Controlled, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy - N/A Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping
MedDRA version: 20.0;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Name: SRP-4045
Product Code: SRP-4045
Other descriptive name: Oligomero morfolino fosforodiamidato per skipping dell’esone 45
Product Name: SRP-4053
Product Code: SRP-4053
Other descriptive name: Oligomero morfolino fosforodiamidato per skipping dell’esone 53
SAREPTA THERAPEUTICS, INC.NULLAuthorised-recruitment may be ongoing or finishedFemale: no
Male: yes
99Phase 3France;Czech Republic;Spain;Belgium;Netherlands;Germany;United Kingdom;Italy;Sweden